RU2340612C2 - 2-имидазобензотиазолы как лиганды аденозинового рецептора - Google Patents

2-имидазобензотиазолы как лиганды аденозинового рецептора Download PDF

Info

Publication number
RU2340612C2
RU2340612C2 RU2005138546/04A RU2005138546A RU2340612C2 RU 2340612 C2 RU2340612 C2 RU 2340612C2 RU 2005138546/04 A RU2005138546/04 A RU 2005138546/04A RU 2005138546 A RU2005138546 A RU 2005138546A RU 2340612 C2 RU2340612 C2 RU 2340612C2
Authority
RU
Russia
Prior art keywords
morpholin
methoxy
lower alkyl
ylbenzothiazol
imidazo
Prior art date
Application number
RU2005138546/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2005138546A (ru
Inventor
Александер ФЛОР (CH)
Александер Флор
Роланд ЯКОБ-РЁТНЕ (DE)
Роланд Якоб-Рётне
Роджер Дейвид НОРКРОСС (CH)
Роджер Дейвид Норкросс
Клаус РИМЕР (DE)
Клаус Ример
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2005138546A publication Critical patent/RU2005138546A/ru
Application granted granted Critical
Publication of RU2340612C2 publication Critical patent/RU2340612C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
RU2005138546/04A 2003-05-13 2004-05-06 2-имидазобензотиазолы как лиганды аденозинового рецептора RU2340612C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US03009842.0 2003-05-13
EP03009842 2003-05-13

Publications (2)

Publication Number Publication Date
RU2005138546A RU2005138546A (ru) 2006-07-27
RU2340612C2 true RU2340612C2 (ru) 2008-12-10

Family

ID=33395778

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005138546/04A RU2340612C2 (ru) 2003-05-13 2004-05-06 2-имидазобензотиазолы как лиганды аденозинового рецептора

Country Status (15)

Country Link
US (1) US7122545B2 (cg-RX-API-DMAC7.html)
EP (1) EP1636217B1 (cg-RX-API-DMAC7.html)
JP (1) JP4408291B2 (cg-RX-API-DMAC7.html)
KR (1) KR100710453B1 (cg-RX-API-DMAC7.html)
CN (1) CN100372844C (cg-RX-API-DMAC7.html)
AT (1) ATE407133T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004238508B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0410315A (cg-RX-API-DMAC7.html)
CA (1) CA2523959A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004016328D1 (cg-RX-API-DMAC7.html)
ES (1) ES2313001T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05012120A (cg-RX-API-DMAC7.html)
PL (1) PL1636217T3 (cg-RX-API-DMAC7.html)
RU (1) RU2340612C2 (cg-RX-API-DMAC7.html)
WO (1) WO2004101558A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453647B2 (en) 2017-08-21 2022-09-27 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists
RU2781429C2 (ru) * 2017-08-21 2022-10-11 Мерк Патент Гмбх Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
CA2756989A1 (en) * 2009-04-03 2010-10-07 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
US10155777B2 (en) 2015-04-08 2018-12-18 University Of Delaware Trans-cycloheptenes and hetero-trans-cycloheptenes for bioorthogonal coupling
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2025160629A1 (en) * 2024-01-31 2025-08-07 Certa Therapeutics Pty Ltd Proton sensing gpcr modulators

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295656A1 (en) * 1987-06-17 1988-12-21 Eisai Co., Ltd. Benzothiazole derivative, its use, and pharmaceutical compositions comprising it
SU1681728A3 (ru) * 1988-05-24 1991-09-30 Пфайзер Инк. (Фирма) Способ получени производных N-(бензтиазолил-2)амидов бензойной или тиазол-4-карбоновой кислоты
US6521754B2 (en) * 2000-06-21 2003-02-18 Hoffman-La Roche Inc. Benzothiazole derivatives with activity as adenosine receptor ligands

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
US6037473A (en) * 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
WO2001002400A1 (en) * 1999-07-02 2001-01-11 Eisai Co., Ltd. Fused imidazole compounds and remedies for diabetes mellitus
EP1628662B1 (en) * 2003-05-21 2007-02-14 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295656A1 (en) * 1987-06-17 1988-12-21 Eisai Co., Ltd. Benzothiazole derivative, its use, and pharmaceutical compositions comprising it
SU1681728A3 (ru) * 1988-05-24 1991-09-30 Пфайзер Инк. (Фирма) Способ получени производных N-(бензтиазолил-2)амидов бензойной или тиазол-4-карбоновой кислоты
US6521754B2 (en) * 2000-06-21 2003-02-18 Hoffman-La Roche Inc. Benzothiazole derivatives with activity as adenosine receptor ligands

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453647B2 (en) 2017-08-21 2022-09-27 Merck Patent Gmbh Benzimidazole derivatives as adenosine receptor antagonists
RU2781429C2 (ru) * 2017-08-21 2022-10-11 Мерк Патент Гмбх Бензимидазольные производные в качестве антагонистов аденозиновых рецепторов

Also Published As

Publication number Publication date
CA2523959A1 (en) 2004-11-25
DE602004016328D1 (de) 2008-10-16
JP2006528215A (ja) 2006-12-14
KR20060009928A (ko) 2006-02-01
RU2005138546A (ru) 2006-07-27
AU2004238508B2 (en) 2009-11-19
KR100710453B1 (ko) 2007-04-24
CN1780831A (zh) 2006-05-31
EP1636217B1 (en) 2008-09-03
US7122545B2 (en) 2006-10-17
AU2004238508A1 (en) 2004-11-25
JP4408291B2 (ja) 2010-02-03
ATE407133T1 (de) 2008-09-15
EP1636217A1 (en) 2006-03-22
US20040229862A1 (en) 2004-11-18
PL1636217T3 (pl) 2009-02-27
MXPA05012120A (es) 2006-02-08
ES2313001T3 (es) 2009-03-01
WO2004101558A1 (en) 2004-11-25
CN100372844C (zh) 2008-03-05
BRPI0410315A (pt) 2006-05-23

Similar Documents

Publication Publication Date Title
JP2005525324A5 (cg-RX-API-DMAC7.html)
RU2003106193A (ru) Способ лечения аллергий с использованием замещенных пиразолов
JP5456891B2 (ja) Cyp17阻害剤としての1,3−二置換イミダゾリジン−2−オン誘導体
JP2024539068A5 (cg-RX-API-DMAC7.html)
JP2021113224A (ja) ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
JP2006524254A5 (cg-RX-API-DMAC7.html)
CA3049643C (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
JP2004520360A5 (cg-RX-API-DMAC7.html)
PE20050756A1 (es) Heterociclicos azabiciclicos como moduladores del receptor cannabinoide
JP2006506352A5 (cg-RX-API-DMAC7.html)
JP2014532626A5 (cg-RX-API-DMAC7.html)
RU2007112110A (ru) Производные пирроло[2.3-с] пиридина и способы их получения
RU2410387C2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-c]ПИРИДИН-4-ОН 2-ИНДОЛИНОНА В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗЫ
RU2005134652A (ru) Конденсированные n-гетероциклические соединения и их применение в качестве антагонистов рецепторов crf
RU2010138928A (ru) Соединение бензодиазепина и фармацевтическая композиция
JP2013545744A5 (cg-RX-API-DMAC7.html)
JP2014516073A5 (cg-RX-API-DMAC7.html)
JP2006522812A5 (cg-RX-API-DMAC7.html)
JP2004534780A5 (cg-RX-API-DMAC7.html)
JP2013515033A5 (cg-RX-API-DMAC7.html)
JP2022502424A5 (cg-RX-API-DMAC7.html)
KR20190110736A (ko) 신규의 트라이아졸론 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
RU2005138546A (ru) 2-имидазобензотиазолы, как лиганды аденозинового рецептора
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20060653A1 (es) Derivados triciclicos condensados como moduladores del receptor 5-ht1

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110507